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Introduction
============

Stroke is one of the major non-communicable diseases causing global burden for its high mortality and morbidity^[@bib1]--[@bib3])^. In Japan, it is currently one of the leading causes of death and was the most prominent killer in the past^[@bib4],\ [@bib5])^. Although being a developed country, Japan still suffers from immense healthcare cost for its stroke survivors^[@bib6])^. Improvement of stroke outcome by refined detection of high-risk patients with poor prognosis is thus mandatory to alleviate the situation. In the past few years, renal dysfunction has been identified as a novel risk factor affecting stroke prognosis, and estimated glomerular filtration rate (eGFR) is one of the parameters used as its proxy^[@bib7]--[@bib17])^. Few, however, have analyzed the association within large-scale population-based setting, using wide-range eGFR category. It is therefore necessary to ascertain it using bigger and more comprehensive data. We aimed to determine the association of on-admission eGFR with in-hospital death and at-discharge death/disability in acute stroke patients using data from a registry established in Shiga Prefecture, Japan.

Methods
=======

Subjects
--------

The Shiga Stroke Registry (SSR) is a multicenter population-based stroke registry developed to provide comprehensive information on acute ischemic and nontraumatic hemorrhagic stroke in Shiga Prefecture, a region populated by 1.4 million people and located in the middle of Honshu Island, Japan^[@bib18])^. Of 41 acute care hospitals inside the prefecture with neurology/neurosurgery facilities, as well as smaller hospitals with rehabilitation facilities, data of all stroke cases were obtained retrospectively from medical records by trained investigators and put together in an encrypted database in Shiga University of Medical Science. Civil registration death certificates were also used to identify stroke cases leading to death outside the hospital. The current study focused on 2,956 stroke patients registered from 1 January to 31 December 2011. Following exclusion of patients younger than 18 years (*n* = 5), with missing admission serum creatinine data (*n* = 65), and with onset more than 7 days prior to admission (*n* = 73), 2,813 acute stroke patients were included in the final analysis. The Institutional Review Board of Shiga University of Medical Science has approved the study protocol.

Determination of Stroke
-----------------------

Stroke was defined as rapidly developing clinical signs of focal or global disturbance of cerebral function, lasting more than 24 h or leading to mortality, with no apparent cause other than that of vascular origin^[@bib19])^. Stroke was further categorized as ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage, with the latter two grouped into hemorrhagic stroke. All cases were confirmed both clinically and radiologically, and the final diagnosis was made by more than 2 independent investigators.

Variables and Outcome
---------------------

Data gathered included age, gender, comorbidities (hypertension, diabetes, myocardial infarction, atrial fibrillation, dyslipidemia), previous stroke, smoking status, admission details (systolic and diastolic blood pressure, modified Rankin Scale (mRS), Japan Coma Scale \[JCS\])^[@bib20])^, interventional/surgical therapy performed, tissue plasminogen activator administered, days from onset until death/hospital discharge, and discharge mRS score. Interventional therapy consisted of endovascular recanalization and coil embolization, whereas surgical therapy involved decompression, hematoma evacuation, cerebrospinal fluid diversion, thrombectomy, and aneurysm clipping by means of endoscopic and/or conventional cranio/ectomy. The outcomes of this study were all-cause in-hospital death (mRS of 6) and atdischarge death/disability (mRS 2--6).

Renal Function Evaluation
-------------------------

Admission serum creatinine was measured using enzymatic method in local laboratories and used to estimate GFR based on the Japanese Society of Nephrology equation: eGFR (mL/min/1.73 m^2^) = 194 × (serum creatinine \[mg/dL\])^−1.094^ × (age \[year\])^−0.287^ × 0.739 (for female)^[@bib21])^. The estimated GFR was then categorized as \< 45, 45--59, 60--89, and ≥ 90 mL/min/1.73 m^2^, with eGFR 60--89 mL/min/1.73 m^2^ being the reference group^[@bib22])^. Patients with eGFR \< 45 mL/min/1.73 m^2^ were pooled together due to small number, whereas patients on renal replacement therapy (RRT) were gathered into a separate group due to their particular feature.

Statistical Analysis
--------------------

Continuous variables were presented as mean (standard deviation) or median (interquartile range) as appropriate, and categorical variables as proportions. Differences in means or medians between two groups were analyzed using Student\'s *t*-test or Mann-Whitney *U* test, respectively, while *χ*^2^ or Fisher exact test was conducted to find differences in proportions as appropriate. Probability trends were determined by treating eGFR in its continuous nature and fitting it into linear/logistic regression models with variables of interest. Next, multivariable logistic regression analyses, adjusting for covariates regarded and/or identified from literatures to be significantly associated with stroke outcomes, were performed to determine the association of eGFR with both outcomes. Separate analyses were done within stroke subtypes. Finally, sensitivity analyses were conducted for the outcome of at-discharge death/dependency (mRS 3--6) on all stroke subtypes. All analyses were conducted using SAS Version 9.4 software (SAS Institute). Differences with two-tailed *p*-value \< 0.05 is considered to be statistically significant.

Results
=======

Characteristics of Patients by RRT Status
-----------------------------------------

**[Table 1](#T1){ref-type="table"}** shows basic characteristics of adult acute stroke patients by RRT status. Compared with non-RRT group, several significant differences were identified in RRT group: patients\' age was younger; hypertension, diabetes, previous stroke, and pre-admission significant disability were more prevalent; admission JCS score was worse; admission eGFR was extremely lower; and in-hospital death was higher.

###### Basic characteristics of study subjects by renal replacement therapy status

                                             Non-RRT             RRT               *p*
  ------------------------------------------ ------------------- ----------------- ----------
  Age, mean years ± SD                       74.1 ± 13.3         70.1 ± 13.4       0.04
  Female, n (%)                              1276 (46.5)         27 (38.6)         0.19
  Comorbidities, n (%)                                                             
      Hypertension                           1973 (72.7)         59 (85.5)         0.02
      Diabetes                               726 (26.7)          30 (43.5)         0.002
      Myocardial infarction                  165 (6.1)           3 (4.4)           0.79
      Atrial fibrillation                    559 (20.6)          15 (22.1)         0.76
      Dyslipidemia                           951 (36.7)          20 (30.8)         0.32
  Previous stroke, n (%)                     706 (25.8)          30 (42.9)         0.001
  Smoking status, n (%)                                                            0.54
      Never                                  1634 (65.6)         38 (63.3)         
      Ex                                     325 (13)            6 (10)            
      Current                                532 (21.4)          16 (26.7)         
  SBP, mean mmHg ± SD                        161.8 ± 33          166.7 ± 41        0.32
  DBP, mean mmHg ± SD                        88.7 ± 20.4         85.8 ± 22.5       0.26
  Japan Coma Scale, n (%)                                                          0.03
      0                                      1241 (45.4)         32 (46.4)         
      1--3 (1-digit)                         693 (25.3)          9 (13)            
      10--30 (2-digit)                       357 (13.1)          9 (13)            
      100--300 (3-digit)                     444 (16.2)          19 (27.6)         
  eGFR, mL/min/1.73 m^2^, median (IQR)       67.5 (52.9--82.7)   6.2 (4.7--10.1)   \< .0001
  Admission mRS, n (%)                                                             \< .0001
      0                                      1703 (62.1)         17 (24.3)         
      1                                      322 (11.7)          17 (24.3)         
      2                                      173 (6.3)           8 (11.4)          
      3                                      212 (7.7)           11 (15.7)         
      4                                      243 (8.9)           11 (15.7)         
      5                                      90 (3.3)            6 (8.6)           
  Intervention/surgery, n (%)                296 (10.8)          9 (12.9)          0.59
  r-tPA, n (%)                               77 (2.8)            1 (1.5)           0.99
  Onset-death/discharge days, median (IQR)   25 (13--46)         19.5 (10--39)     0.09
  Final diagnosis, n (%)                                                           0.83
      Ischemic                               1803 (65.7)         45 (64.3)         
      Haemorrhagic                           935 (34.1)          25 (35.7)         
  Discharge mRS, n (%)                                                             0.09
      0                                      202 (7.4)           4 (5.7)           
      1                                      509 (18.6)          11 (15.7)         
      2                                      318 (11.6)          8 (11.4)          
      3                                      287 (10.5)          8 (11.4)          
      4                                      628 (22.9)          11 (15.7)         
      5                                      390 (14.2)          8 (11.4)          
  In-hospital death, n (%)                   409 (14.9)          20 (28.6)         0.002

RRT, renal replacement therapy; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; mRS, modified Rankin Scale; r-tPA, recombinant tissue plasminogen activator

Characteristics of Study Subjects by eGFR Category
--------------------------------------------------

**[Table 2](#T2){ref-type="table"}** presents basic characteristics of study subjects by eGFR category. Of 2,743 non-RRT patients, 15.7% presented with eGFR of \< 45 mL/min/1.73 m^2^, 20.8% with eGFR 45--59 mL/min/1.73 m^2^, 47.6% with eGFR 60--89 mL/min/1.73 m^2^, and 15.9% with eGFR ≥90 mL/min/1.73 m^2^. Compared to other groups, in the eGFR ≤ 45 mL/min/1.73 m^2^ group, patients were significantly older; prevalence of hypertension, diabetes, myocardial infarction, atrial fibrillation, recurrent stroke, and never smokers were higher; admission systolic and diastolic blood pressure were lower, admission mRS and JCS were worse, intervention/surgery was less performed, and, lastly, ischemic stroke was more prevalent.

###### Characteristics of the study subjects not on renal replacement therapy

                                             eGFR (mL/min/1.73 m^2^)                                                
  ------------------------------------------ ------------------------- -------------- -------------- -------------- ----------
  Age, mean years ± SD                       80.9 ± 10.9               78 ± 10.4      72.5 ± 12.9    66.7 ± 15.4    \< .0001
  Female, n (%)                              229 (53.1)                265 (46.4)     572 (43.8)     210 (48.3)     0.25
  Comorbidities, n (%)                                                                                              
      Hypertension                           351 (82.4)                433 (76.6)     917 (70.8)     272 (63.6)     \< .0001
      Diabetes                               152 (35.8)                141 (24.7)     329 (25.3)     104 (24.3)     0.001
      Myocardial infarction                  45 (10.6)                 39 (6.9)       61 (4.7)       20 (4.6)       \< .0001
      Atrial fibrillation                    135 (31.8)                145 (25.6)     226 (17.4)     53 (12.2)      \< .0001
      Dyslipidemia                           136 (33.8)                210 (38.9)     462 (37.4)     143 (35)       0.67
  Previous stroke, n (%)                     126 (29.6)                176 (30.9)     322 (24.7)     82 (18.9)      \< .0001
  Smoking status, n (%)                                                                                             \< .0001
      Never                                  283 (74.3)                364 (70.8)     751 (62.7)     236 (59.2)     
      Ex                                     52 (13.7)                 74 (14.4)      153 (12.8)     46 (11.5)      
      Current                                46 (12.1)                 76 (14.8)      293 (24.5)     117 (29.3)     
  SBP, mean mmHg ± SD                        157.2 ± 35.1              160.3 ± 32.8   163.7 ± 32.1   162.4 ± 33.4   0.05
  DBP, mean mmHg ± SD                        83.1 ± 20.9               86.9 ± 21.4    90.5 ± 19.8    90.9 ± 19.4    \< .0001
  Japan Coma Scale, n (%)                                                                                           0.03
      0                                      140 (32.6)                258 (45.2)     651 (50)       192 (44.4)     
      1--3 (1-digit)                         127 (29.6)                158 (27.7)     314 (24.1)     94 (21.8)      
      10--30 (2-digit)                       58 (13.5)                 77 (13.5)      164 (12.6)     58 (13.4)      
      100--300 (3-digit)                     104 (24.2)                78 (13.7)      174 (13.4)     88 (20.4)      
  eGFR, mean mL/min/1.73 m^2^ ± SD           33.4 ± 9.5                53.4 ± 4.1     73.7 ± 8.4     108.5 ± 21.2   \< .0001
  Admission mRS, n (%)                                                                                              \< .0001
      0                                      205 (47.6)                316 (55.3)     872 (66.8)     310 (71.3)     
      1                                      59 (13.7)                 79 (13.8)      152 (11.6)     32 (7.4)       
      2                                      36 (8.4)                  41 (7.2)       79 (6.1)       17 (3.9)       
      3                                      59 (13.7)                 59 (10.3)      80 (6.1)       14 (3.2)       
      4                                      58 (13.5)                 60 (10.5)      93 (7.1)       32 (7.4)       
      5                                      14 (3.3)                  16 (2.8)       30 (2.3)       30 (6.9)       
  Intervention/surgery, n (%)                29 (6.8)                  44 (7.7)       137 (10.5)     86 (19.8)      \< .0001
  tPA, n (%)                                 11 (2.6)                  22 (3.9)       38 (2.9)       6 (1.4)        0.31
  Onset-death/discharge days, median (IQR)   24 (12--51)               27 (13--48)    25 (13--45)    25 (13--46)    0.36
  Final diagnosis, n (%)                                                                                            \< .0001
      Ischemic                               322 (74.7)                418 (73.2)     850 (65.1)     213 (49)       
      Haemorrhagic                           108 (25.1)                153 (26.8)     455 (34.8)     219 (50.3)     

SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; mRS, modified Rankin Scale; tPA, tissue plasminogen activator

Prevalence of Outcomes by eGFR Category and the Association of eGFR with Outcomes in All Stroke
-----------------------------------------------------------------------------------------------

**[Table 3](#T3){ref-type="table"}** shows prevalence of outcomes by eGFR category and the association of eGFR with outcomes in all stroke. Both in-hospital death and at-discharge death/disability display reverse relationship with eGFR. For multivariable adjustment, age, sex, hypertension, diabetes, myocardial infarction, atrial fibrillation, previous stroke, smoking status, diastolic blood pressure, admission JCS and mRS, intervention/surgery, and recombinant tissue plasminogen activator administration were selected as covariates. Compared to the reference group, only eGFR \< 45 mL/min/1.73 m^2^ group maintained its significant association with in-hospital death (from unadjusted OR \[95% CI\] of 2.70 \[2.05--3.55\] to multivariable-adjusted OR \[95% CI\] of 1.54 \[1.05--2.27\]) and with at-discharge death/disability (from unadjusted OR \[95% CI\] of 2.94 \[2.17--4.00\] to multivariable-adjusted OR \[95% CI\] of 1.54 \[1.02--2.32\]). Moreover, following further adjustment, a maintained significant association with at-discharge disability was seen in eGFR \> 90 mL/min/1.73 m^2^ group (multivariable-adjusted OR \[95% CI\] of 1.48 \[1.06--2.05\]). RRT group, particularly, did not display any significant association with both outcomes after adjustments.

###### Prevalence and odds ratio (95% confidence interval) of each eGFR category for outcomes in all stroke

                                                eGFR (mL/min/1.73 m^2^)                                                        
  --------------------------------------------- ------------------------- ------------------- ------------------- ------------ -------------------
  *Death (mRS 6)*                                                                                                              
      N (%)                                     20 (28.6)                 113 (26.2)          81 (14.2)           152 (11.6)   63 (14.5)
      Unadjusted                                3.04 (1.76--5.24)         2.70 (2.05--3.55)   1.26 (0.94--1.68)   1.00         1.29 (0.94--1.76)
      Model 1^[a](#tf1){ref-type="table-fn"}^   3.33 (1.91--5.81)         2.09 (1.57--2.77)   1.06 (0.79--1.43)   1.00         1.55 (1.12--2.14)
      Model 2^[b](#tf2){ref-type="table-fn"}^   2.03 (0.90--4.58)         1.54 (1.05--2.27)   1.07 (0.72--1.58)   1.00         1.04 (0.67--1.59)
  *Death/disability (mRS 2--6)*                                                                                                
      N (%)                                     55 (78.6)                 376 (87.2)          437 (76.5)          913 (69.9)   306 (70.3)
      Unadjusted                                1.58 (0.88--2.83)         2.94 (2.17--4.00)   1.40 (1.12--1.76)   1.00         1.02 (0.81--1.30)
      Model 1^[a](#tf1){ref-type="table-fn"}^   1.87 (1.01--3.46)         1.95 (1.42--2.69)   1.04 (0.82--1.33)   1.00         1.40 (1.08--1.82)
      Model 2^[b](#tf2){ref-type="table-fn"}^   0.89 (0.39--2.03)         1.54 (1.02--2.32)   0.97 (0.73--1.31)   1.00         1.48 (1.06--2.05)

eGFR, estimated glomerular filtration rate; RRT, renal replacement therapy; mRS, modified Rankin Scale

Adjusted for age and sex

Adjusted for age, sex, hypertension, diabetes, myocardial infarction, atrial fibrillation, previous stroke, smoking status, diastolic blood pressure, admission Japan Coma Scale and modified Rankin Scale, intervention/surgery, and recombinant tissue plasminogen activator administration

All regression analyses result are in odds ratio (95% confidence interval)

Prevalence of Outcomes by eGFR Category and the Association of eGFR with Outcomes in Ischemic and Hemorrhagic Strokes
---------------------------------------------------------------------------------------------------------------------

**[Tables 4](#T4){ref-type="table"}** and **[5](#T5){ref-type="table"}** show prevalence of outcomes by eGFR category and the association of eGFR with outcomes in ischemic and hemorrhagic strokes. In-hospital death and at-discharge death/disability had similar reverse relationship with eGFR in both stroke subtypes as in all stroke. In the same manner, eGFR \< 45 mL/min/1.73 m^2^ group in ischemic stroke displayed maintained significant association with in-hospital death (from unadjusted OR \[95% CI\] of 3.46 \[2.37--5.05\] to multivariable-adjusted OR \[95% CI\] of 1.60 \[1.00--2.57\]) and with at-discharge disability (from unadjusted OR \[95% CI\] of 3.53 \[2.50--4.99\] to multivariable-adjusted OR \[95% CI\] of 1.74 \[1.10--2.76\]). Still within the same stroke subtype, eGFR \> 90 mL/min/1.73 m^2^ group also showed maintained significant association with at-discharge disability (multivariable-adjusted OR \[95% CI\] of 1.52 \[1.01--2.31\]). As for hemorrhagic stroke, with the exception of RRT group that preserved its significant association with in-hospital death (from unadjusted OR \[95% CI\] of 3.64 \[1.61--8.25\] to multivariable-adjusted OR \[95% CI\] of 5.27 \[1.43--19.50\]), no other significant associations were identified.

###### Prevalence and odds ratio (95% confidence interval) of each eGFR category for outcomes in ischemic stroke

                                                eGFR (mL/min/1.73 m^2^)                                                        
  --------------------------------------------- ------------------------- ------------------- ------------------- ------------ -------------------
  *Death (mRS 6)*                                                                                                              
      N (%)                                     8 (17.8)                  66 (20.5)           46 (11)             59 (6.9)     18 (8.5)
      Unadjusted                                2.90 (1.29--6.51)         3.46 (2.37--5.05)   1.66 (1.11--2.49)   1.00         1.24 (0.71--2.15)
      Model 1^[a](#tf3){ref-type="table-fn"}^   2.97 (1.29--6.85)         2.17 (1.46--3.23)   1.26 (0.83--1.91)   1.00         1.66 (0.94--2.92)
      Model 2^[b](#tf4){ref-type="table-fn"}^   0.91 (0.27--3.07)         1.60 (1.00--2.57)   1.20 (0.74--1.94)   1.00         0.92 (0.45--1.86)
  *Death/disability (mRS 2--6)*                                                                                                
      N (%)                                     35 (77.8)                 277 (86)            305 (73)            540 (63.5)   133 (62.4)
      Unadjusted                                2.01 (0.98--4.11)         3.53 (2.50--4.99)   1.55 (1.20--2.00)   1.00         0.95 (0.70--1.30)
      Model 1^[a](#tf3){ref-type="table-fn"}^   1.89 (0.89--4.02)         2.08 (1.44--3.01)   1.02 (0.78--1.35)   1.00         1.41 (0.99--2.00)
      Model 2^[b](#tf4){ref-type="table-fn"}^   0.96 (0.36--2.57)         1.74 (1.10--2.76)   0.91 (0.65--1.28)   1.00         1.54 (1.02--2.33)

eGFR, estimated glomerular filtration rate; RRT, renal replacement therapy; mRS, modified Rankin Scale

Adjusted for age and sex

Adjusted for age, sex, hypertension, diabetes, myocardial infarction, atrial fibrillation, previous stroke, smoking status, diastolic blood pressure, admission Japan Coma Scale and modified Rankin Scale, intervention/surgery, and recombinant tissue plasminogen activator administration

All regression analyses result are in odds ratio (95% confidence interval)

###### Prevalence and odds ratio (95% confidence interval) of each eGFR category for outcomes in hemorrhagic stroke

                                                eGFR (mL/min/1.73 m^2^)                                                        
  --------------------------------------------- ------------------------- ------------------- ------------------- ------------ -------------------
  *Death (mRS 6)*                                                                                                              
      N (%)                                     12 (48)                   46 (42.6)           35 (22.9)           92 (20.2)    42 (19.2)
      Unadjusted                                3.64 (1.61--8.25)         2.93 (1.88--4.57)   1.17 (0.75--1.82)   1.00         0.94 (0.62--1.41)
      Model 1^[a](#tf5){ref-type="table-fn"}^   4.53 (1.92--10.66)        2.46 (1.56--3.88)   1.05 (0.67--1.64)   1.00         1.09 (0.72--1.66)
      Model 2^[b](#tf6){ref-type="table-fn"}^   5.27 (1.43--19.50)        1.66 (0.80--3.42)   0.85 (0.42--1.72)   1.00         1.00 (0.54--1.83)
  *Death/disability (mRS 2--6)*                                                                                                
      N (%)                                     20 (80)                   98 (90.7)           132 (86.3)          372 (81.8)   170 (77.6)
      Unadjusted                                0.89 (0.33--2.45)         2.19 (1.09--4.37)   1.40 (0.84--2.36)   1.00         0.77 (0.52--1.15)
      Model 1^[a](#tf5){ref-type="table-fn"}^   1.30 (0.45--3.77)         1.61 (0.79--3.28)   1.20 (0.70--2.05)   1.00         1.04 (0.68--1.58)
      Model 2^[b](#tf6){ref-type="table-fn"}^   0.51 (0.11--2.25)         0.71 (0.28--1.81)   1.08 (0.55--2.12)   1.00         1.18 (0.68--2.06)

eGFR, estimated glomerular filtration rate; RRT, renal replacement therapy; mRS, modified Rankin Scale

Adjusted for age and sex

Adjusted for age, sex, hypertension, diabetes, myocardial infarction, atrial fibrillation, previous stroke, smoking status, diastolic blood pressure, admission Japan Coma Scale and modified Rankin Scale, intervention/surgery, and recombinant tissue plasminogen activator administration

All regression analyses result are in odds ratio (95% confidence interval)

Sensitivity Analyses: The Association of eGFR With At-Discharge Death/Dependency in All Strokes and Its Subtypes
----------------------------------------------------------------------------------------------------------------

**[Table 6](#T6){ref-type="table"}** presents the association of eGFR with at-discharge death/dependency in all strokes and its subtypes as sensitivity analyses. Compared to the reference group, significant association was maintained only in eGFR \< 45 mL/min/1.73 m^2^ in ischemic stroke (from unadjusted OR \[95% CI\] of 3.56 \[2.50--4.99\] to multivariable-adjusted OR \[95% CI\] of 1.74 \[1.10--2.76\]).

###### Prevalence and odds ratio (95% confidence interval) of each eGFR category for death/dependency (mRS 3--6) in all stroke and its subtypes

                                                eGFR (mL/min/1.73 m^2^)                                                  
  --------------------------------------------- ------------------------- ------------------- ------------------- ------ -------------------
  *All stroke*                                                                                                           
      Unadjusted                                1.48 (0.89--2.47)         2.75 (2.13--3.55)   1.27 (1.03--1.55)   1.00   1.01 (0.81--1.26)
      Model 1^[a](#tf7){ref-type="table-fn"}^   1.82 (1.05--3.15)         1.79 (1.36--2.36)   0.92 (0.74--1.15)   1.00   1.41 (1.10--1.80)
      Model 2^[b](#tf8){ref-type="table-fn"}^   1.02 (0.46--2.27)         1.23 (0.85--1.79)   0.77 (0.57--1.03)   1.00   1.32 (0.94--1.84)
  *Ischemic stroke*                                                                                                      
      Unadjusted                                1.89 (1.01--3.53)         3.56 (2.65--4.77)   1.52 (1.20--1.93)   1.00   0.98 (0.72--1.32)
      Model 1^[a](#tf7){ref-type="table-fn"}^   1.87 (0.95--3.71)         2.07 (1.50--2.86)   1.01 (0.78--1.31)   1.00   1.49 (1.05--2.11)
      Model 2^[b](#tf8){ref-type="table-fn"}^   1.18 (0.46--3.05)         1.54 (1.01--2.35)   0.81 (0.57--1.14)   1.00   1.56 (1.00--2.45)
  *Hemorrhagic stroke*                                                                                                   
      Unadjusted                                0.87 (0.35--2.14)         1.81 (1.04--3.17)   1.02 (0.67--1.56)   1.00   0.69 (0.49--0.98)
      Model 1^[a](#tf7){ref-type="table-fn"}^   1.39 (0.53--3.68)         1.27 (0.71--2.28)   0.83 (0.53--1.30)   1.00   0.94 (0.64--1.38)
      Model 2^[b](#tf8){ref-type="table-fn"}^   0.54 (0.13--2.29)         0.49 (0.22--1.10)   0.63 (0.35--1.17)   1.00   0.91 (0.54--1.52)

eGFR, estimated glomerular filtration rate; RRT, renal replacement therapy; mRS, modified Rankin Scale

Adjusted for age and sex

Adjusted for age, sex, hypertension, diabetes, myocardial infarction, atrial fibrillation, previous stroke, smoking status, diastolic blood pressure, admission Japan Coma Scale and modified Rankin Scale, intervention/surgery, and recombinant tissue plasminogen activator administration

All regression analyses result are in odds ratio (95% confidence interval)

Discussion
==========

In the current study, low eGFR (\< 45 mL/min/1.73 m^2^) was shown to be significantly and positively associated with all stroke outcome: its ORs for in-hospital death and at-discharge death/disability were 1.54 times higher than the reference group. Additionally, high eGFR (≥ 90 mL/min/1.73 m^2^) was significantly associated with at-discharge death/disability, its OR was 1.48 higher than the reference group. Further analyses within each stroke subtypes, as well as sensitivity analyses, discovered the same pattern to be strongly evident in the ischemic stroke. In regard to RRT patients, this group displayed a notable association with death only within hemorrhagic stroke.

Despite growing interest in similar subject, divulging the association either in overall stroke^[@bib7]--[@bib9])^, ischemic^[@bib10]--[@bib14])^ or hemorrhagic subtypes^[@bib15]--[@bib17])^, in-between study findings have been contradictory, for example, while Yahalom *et al* ^[@bib9])^ and Tsagalis *et al* ^[@bib7])^ showed significant and positive result between low eGFR and mortality and poor outcome after stroke, the opposite was reported by Yang *et al* ^[@bib8])^. Result interpretations were complicated by small sample size^[@bib7]--[@bib9],\ [@bib12]--[@bib15],\ [@bib17])^, non-population-based setting^[@bib7]--[@bib9],\ [@bib11],\ [@bib12],\ [@bib14])^, narrow-range eGFR category^[@bib7],\ [@bib11],\ [@bib13]--[@bib15])^, or lack of control for stroke severity^[@bib12],\ [@bib15])^. The present study deals with these issues by employing data from a large-scale population-based setting registry, implementing wide-range eGFR category, and separating analyses between non-RRT and RRT patients. The latter, particularly, is paramount as serum creatinine level in RRT patients is unreliable; thus, its inclusion will confound the study results^[@bib23])^.

The mechanism underlying the relationship between renal function and poor stroke outcome has not been clearly understood. In our study, low eGFR group exhibited the highest prevalence of traditional vascular risk factors linked to stroke, e.g. hypertension, diabetes, and aging, all were perceived to cause poor outcome^[@bib13])^. Various theories have been proposed to explain this, from aging-related mechanism^[@bib24],\ [@bib25])^ to structure-related mechanisms of renal and cerebral blood vessels^[@bib26],\ [@bib27])^. These theories, especially the one related to aging and atherosclerosis, may explain our finding related to the detrimental effect of low eGFR, especially in patients with ischemic stroke. Although atherosclerosis of large cerebral arteries was reported to be related to the development of atherothrombotic brain infarction, the role of serum high-density lipoprotein cholesterol and non--high-density lipoprotein cholesterol may be different in both stroke subtypes^[@bib28],\ [@bib29])^. On the contrary, the adverse outcome in relation to high eGFR found in this study is probably related to kidney hyper filtration, which has been associated with unfavorable cardiovascular outcomes^[@bib10],\ [@bib30])^. High eGFR, however, may not represent true renal function in patients with atypically reduced muscle mass, such as the elderly, amputees, and others suffering from chronic muscle diseases^[@bib31],\ [@bib32])^. Vis-à-vis the association of RRT with in-hospital death within hemorrhagic stroke, similar result was identified in a study by Lin *et al* ^[@bib33])^, in which prior stroke and diabetes, both were prevalent among RRT group in our study, strongly predict mortality in this particular group. A more extensive investigation in the future on this particular issue will be of importance. In addition, we realize that our finding is inconsistent with other studies describing the "U"- or "J"-shaped association^[@bib12],\ [@bib14])^. This may be due to inevitable differences in study population, eGFR equations, or study design. Recently, non-traditional vascular risk factors, such as oxidative stress, decreased platelet function, and anemia caused by reduced erythropoietin production^[@bib34],\ [@bib35])^, have been suggested to adding up clot formation and infarct growth by decreasing perfusion distal to obstruction. They might also contribute to secondary cerebral injury due to metabolic stress and tissue hypoxia^[@bib36])^, promoting hematoma growth and perihematomal edema, eventually worsening hemorrhagic stroke outcome^[@bib17],\ [@bib37])^.

As a consequence of undesirable effects associated with renal dysfunction, a more vigilant management of acute stroke patients with this condition is warranted. Increased risk of intracerebral hemorrhage with thrombolysis administration^[@bib38])^, decreased responsiveness of antiplatelet^[@bib39])^, and limited use of anticoagulants^[@bib40])^ are few of the limitations critical to be recognized in providing medical therapy to these high-risk patients. Should any indication for interventional/surgical therapy arise, cautious peri-, intra-, and postoperative management is imperative, covering aspects such as fluid and electrolytes therapy, anesthetic agent selection, and contrast agent use^[@bib41],\ [@bib42])^. Promotion and preventive measures to manage cardiovascular disease risk factors in community level, specifically in renal dysfunction patients, is of no less importance. A recent study investigating lipid management targets in Japan showed inadequate attainment rates in the population, raising alarm for its improvement^[@bib43])^.

Besides the aforementioned strength of this study, eGFR 60--89 mL/min/1.73 m^2^ was selected as the reference group, considering the specific range of which to better represent the aging nature of stroke patients by taking into account study subjects\' mean eGFR and age. However, because only Japanese patients were studied, results may not be applicable to other populations. Serum creatinine was only measured on admission and in individual centers, thereby influencing its accuracy. Furthermore, admission NIHSS, a strong predictor of stroke outcome^[@bib43])^, was not incorporated due to its high rate of missing data. However, we perceive this issue to be overcome by using JCS, a Japanese-based consciousness level score developed in the same year as the Glasgow Coma Scale, which has been proven to have good predictability of stroke outcome^[@bib22])^.

In conclusion, our study has ascertained that in acute stroke, particularly in ischemic stroke, low eGFR was associated with in-hospital death and at-discharge death/disability. Additionally, high eGFR was also found to be associated with at-discharge death/disability. These findings reemphasize the importance of having great awareness among clinicians managing these stroke patients with renal dysfunction.
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